StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 6.8
Power Rank trend -> Falling
03/27/2025 16:22:00 EST
Amgen Inc (AMGN)
Industry: Drug Manufacturers - General
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, AMGN has been trading in a range between $327.36 and $305.82 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Upside / Downside Potential
Amgen Inc $AMGN entered a Red zone 3 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $319.3523, a potential upside of 4.46% from the recent price of 305.71. The stock is trading 10.88% (potential upside) below its 52 week high of $338.98 and 21.67 % (potential downside) above its 52 week low of $251.27 - based on the recent price.
Company Summary
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
News
| Biopharma firms with foreign exposure face disruption as Trump's tariffs loom The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions. Source: Proactive Investors Thu, 27 Mar 2025 13:20:27 -0400 Sentiment: Negative |
| Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector. Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector. Source: Market Watch Thu, 27 Mar 2025 10:22:00 -0400 Sentiment: Negative |
| Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies. Source: CNBC Television Wed, 26 Mar 2025 13:37:03 -0400 Sentiment: Positive |
| Why Pharma and Biotech Stocks Got Thrashed on Tuesday As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded down a wide variety of stocks in both fields. Source: The Motley Fool Tue, 25 Mar 2025 18:47:05 -0400 Sentiment: Negative |
| Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note In the latest trading session, Amgen (AMGN) closed at $314.38, marking a -0.53% move from the previous day. Source: Zacks Investment Research Mon, 24 Mar 2025 18:55:40 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 338.9803 52 Week Low: 251.27 Beta: 0.524 50 Day MA: 299.8874 200 Day MA: 306.6497 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.187 Qtr Revenue Growth YOY: 0.109 Forward PE: 14.771 Trailing PE: 40.4993